Prostate cancer is a highly heterogeneous disease, and represents one of the most clinically common malignancies in men. Despite the improvement in the management of localized prostate cancer, therapy options for the advanced stages of the disease remain limited. Limited understanding of the extent of cellular plasticity, clonality, and intratumoral heterogeneity in the context of therapy resistance remains one of the main bottlenecks of current prostate cancer research. There are an increased number of novel drugs available, however the mechanisms that are relevant to therapy resistance are incompletely understood and additional studies are needed. The ultimate goal may be to establish evidence-based drug sequences on the basis of understanding the action of transcription factors, oncogenic, and tumor-suppressive miRNA in prostate cancer. Another challenge for experimental therapy is the existence of stem cells which may be targeted by some drugs originally implemented in non-malignant diseases.
The aim of this Research Topic is to cover promising, recent, and novel research trends in prostate cancer research. Despite the general improvement of cancer therapy efficacy, benefits for prostate cancer patients in advanced stages are rather limited. A better understanding of the heterogeneity and plasticity of prostate cancer, and its relation to therapy and disease progression, might identify novel strategies for effective treatment. Novel insights into the role of transcription factors and specific regulatory miRNA are particularly interesting. Experimental studies and early clinical trials will be considered.
We welcome the submission of all article types, including Original Research, Review, Mini-Review, Methods, and Hypothesis and Theory, which cover (but are not limited to) the following areas:
• Single cell studies focused on lineage plasticity and heterogeneity of prostate cancer
• Therapeutic strategies focused on prostate cancer plasticity and heterogeneity
• Circulating tumor cells
• Novel biomarkers in prostate cancer cell subpopulations
• Plasticity/heterogeneity and chemotherapy/chemoresistance
• miRNA profiling and functional studies relevant to cellular plasticity
• Drug repurposing: identification of novel drugs which may have an unexpected effect on heterogeneous prostate cancer cell populations
Prostate cancer is a highly heterogeneous disease, and represents one of the most clinically common malignancies in men. Despite the improvement in the management of localized prostate cancer, therapy options for the advanced stages of the disease remain limited. Limited understanding of the extent of cellular plasticity, clonality, and intratumoral heterogeneity in the context of therapy resistance remains one of the main bottlenecks of current prostate cancer research. There are an increased number of novel drugs available, however the mechanisms that are relevant to therapy resistance are incompletely understood and additional studies are needed. The ultimate goal may be to establish evidence-based drug sequences on the basis of understanding the action of transcription factors, oncogenic, and tumor-suppressive miRNA in prostate cancer. Another challenge for experimental therapy is the existence of stem cells which may be targeted by some drugs originally implemented in non-malignant diseases.
The aim of this Research Topic is to cover promising, recent, and novel research trends in prostate cancer research. Despite the general improvement of cancer therapy efficacy, benefits for prostate cancer patients in advanced stages are rather limited. A better understanding of the heterogeneity and plasticity of prostate cancer, and its relation to therapy and disease progression, might identify novel strategies for effective treatment. Novel insights into the role of transcription factors and specific regulatory miRNA are particularly interesting. Experimental studies and early clinical trials will be considered.
We welcome the submission of all article types, including Original Research, Review, Mini-Review, Methods, and Hypothesis and Theory, which cover (but are not limited to) the following areas:
• Single cell studies focused on lineage plasticity and heterogeneity of prostate cancer
• Therapeutic strategies focused on prostate cancer plasticity and heterogeneity
• Circulating tumor cells
• Novel biomarkers in prostate cancer cell subpopulations
• Plasticity/heterogeneity and chemotherapy/chemoresistance
• miRNA profiling and functional studies relevant to cellular plasticity
• Drug repurposing: identification of novel drugs which may have an unexpected effect on heterogeneous prostate cancer cell populations